OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.

Proteonomix, Inc. (OTCBB: PROT) Has Plans to Advance Drug Therapy for Patients with End Stage Liver Disease but will Biotech's Financial Condition Stunt Growth?

Posted on January 30, 2012 by OTC Equity

Proteonomix, Inc. (OTCBB: PROT) enjoyed incredible growth last week, moving from a 2.35 opening on Monday to a 6.43 closing on Friday; producing an unbelievable payday for those investors who managed to build a sizeable position in the biotechnology company when shares were sitting at a 52-week low of 0.30 back on December 28, 2011. While PROT, which focuses on developing therapeutics based upon the use of human cells and their derivatives, spiked last week there has been a steady pullback this morning as shares have dropped to 5.83, causing considerable panic among those investors who bought on the high end last Friday, a day that saw shares hit a 52-week high of 7.18. The pullback should come as no surprise given the simple fact that PROT didn't release any groundbreaking news last week. In fact, the only press release PROT distributed last week concerned their upcoming p...

To read the complete article sign up below; registration is free, you will only be asked to provide a valid email.

If you are not a registered user, registration is quick and easy - simply enter your email below and you are registered to view OTCEquity's Exclusive content. Your registration and membership is FREE, so register below now.